Crinetics Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US22663K1079

SecurityCRNX / Crinetics Pharmaceuticals, Inc.
InstitutionCitigroup Inc
Latest Disclosed Ownership25,087 shares
Latest Disclosed Value $ 911,160
Citigroup Inc reports 53.56% increase in ownership of CRNX / Crinetics Pharmaceuticals, Inc.

On May 11, 2026 - Citigroup Inc filed a 13F-HR form disclosing ownership of 25,087 shares of Crinetics Pharmaceuticals, Inc. (US:CRNX) valued at $911,160 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 16,337 shares of Crinetics Pharmaceuticals, Inc.. This represents a change in shares of 53.56% during the quarter. The current value of the position is $830,129 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-11 2026-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 25,087 8,750 53.56 911 19.87 0.0002
2026-02-13 2025-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 16,337 -4,459 -21.44 760 -12.24 0.0003
2025-11-10 2025-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 20,796 -35,983 -63.37 866 -46.94 0.0004
2025-08-11 2025-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 56,779 -93,271 -62.16 1,633 -67.57 0.0008
2025-05-12 2025-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 150,050 29,291 24.26 5,033 -18.50 0.0026
2025-02-12 2024-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 120,759 55,934 86.28 6,174 86.41 0.0037
2024-11-12 2024-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 64,825 33,755 108.64 3,313 138.10 0.0019
2024-08-12 2024-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 31,070 -216,980 -87.47 1,392 -88.02 0.0009
2024-05-10 2024-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 248,050 145,739 142.45 11,611 218.98 0.0076
2024-02-09 2023-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 102,311 18,539 22.13 3,640 46.13 0.0026
2023-12-06 2023-09-30 13F/A-1 CRINETICS PHARMACEUTICALS IN COM 22663K107 83,772 28,388 51.26 2,491 149.60 0.0019
2023-11-09 2023-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 83,772 28,388 2,491 0.0007
2023-08-10 2023-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 55,384 -48,433 -46.65 998 -40.13 0.0007
2023-05-11 2023-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 103,817 54,946 112.43 1,667 86.47 0.0012
2023-02-09 2022-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 48,871 -21,615 -30.67 894 -35.40 0.0007
2022-11-10 2022-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 70,486 20,506 41.03 1,384 48.50 0.0010
2022-08-10 2022-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 49,980 34,510 223.08 932 174.12 0.0007
2022-05-12 2022-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 15,470 -36,753 -70.38 340 -77.09 0.0002
2022-02-10 2021-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 52,223 28,460 119.77 1,484 196.80 0.0008
2021-11-10 2021-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 23,763 19,122 412.02 500 474.71 0.0003
2021-08-10 2021-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 4,641 1,835 65.40 87 102.33 0.0001
2021-05-13 2021-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 2,806 -7,455 -72.65 43 -70.34 0.0000
2021-02-11 2020-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 10,261 5,254 104.93 145 85.90 0.0001
2020-11-12 2020-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 5,007 -1,563 -23.79 78 -32.17 0.0001
2020-08-12 2020-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 6,570 3,353 104.23 115 144.68 0.0001
2020-05-12 2020-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 3,217 966 42.91 47 -16.07 0.0000
2020-02-12 2019-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 2,251 1,067 90.12 56 211.11 0.0000
2019-11-08 2019-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 1,184 -2,459 -67.50 18 -80.43 0.0000
2019-08-12 2019-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 3,643 933 34.43 92 50.82 0.0001
2019-05-13 2019-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 2,710 1,209 80.55 61 35.56 0.0001
2019-02-12 2018-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 1,501 -445 -22.87 45 -19.64 0.0000
2018-11-13 2018-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 1,946 1,946 56 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.